Research programme: antimalarials - Sanofi Genzyme

Drug Profile

Research programme: antimalarials - Sanofi Genzyme

Latest Information Update: 20 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Broad Institute; Genzyme Corporation; Harvard University
  • Developer Broad Institute; Harvard University; Medicines for Malaria Venture; Sanofi Genzyme
  • Class
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Heat-shock protein inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 31 Dec 2010 This programme is still in active development
  • 26 Aug 2008 Advinus Therapeutics joins the collaboration for the development of Malaria treatments
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top